Anchang Yuyang Decoction inhibits experimental colitis-related carcinogenesis by regulating PPAR signaling pathway and affecting metabolic homeostasis of host and microbiota

Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 326, P. 117995 - 117995

Published: Feb. 28, 2024

Inflammatory bowel disease (IBD) presents a risk of carcinogenesis, which escalates with the duration IBD. Persistent histological inflammation is considered to be driving factor colitis carcinogenesis. Effective control helpful prevent and treat colitis-related colorectal cancer (CAC). Anchang Yuyang Decoction (AYD), traditional Chinese medicine (TCM) formula, originated from ancient prescription TCM for treating cancer. AYD has demonstrated efficacy in IBD potential anti-carcinogenic properties.

Language: Английский

---

Short Chain Fatty Acids: Essential Weapons of Traditional Medicine in Treating Inflammatory Bowel Disease

Molecules, Journal Year: 2024, Volume and Issue: 29(2), P. 379 - 379

Published: Jan. 12, 2024

Inflammatory bowel disease (IBD) is a chronic and recurrent intestinal inflammatory disease, mainly including Crohn's (CD) ulcerative colitis (UC). In recent years, the incidence prevalence of IBD have been on rise worldwide become significant concern health huge economic burden patients. The occurrence development involve variety pathogenic factors. changes in short-chain fatty acids (SCFAs) are considered to be an important mechanism this disease. SCFAs metabolites microbial environment, which closely involved regulating immune, anti-tumor, anti-inflammatory activities. Changes metabolite levels can reflect homeostasis microflora. Recent studies shown that provide energy for host cells microflora, shape regulate immune system, thereby physiology. effectively reduce enteritis, cardiovascular colon cancer, obesity, diabetes, also play role maintaining balance metabolism (mainly glucose metabolism) improving insulin tolerance. many numerous decoctions natural compounds traditional Chinese medicine promising therapeutic activities multiple animal models thus attracted increasing attention from scientists study treatment. Some these medicines or alleviate colonic inflammation clinical symptoms by generation SCFAs. This reviews effects various bioactive substances production their potential impacts severity inflammation. On basis, we discussed IBD-associated inflammation, as well related regulatory factors signaling pathways. addition, our understanding limitations current research prospects future new therapies targeting review may widen effect view alleviating models, contributing researchers.

Language: Английский

---

Akkermansia muciniphila relieves inflammatory response in DSS-induced ulcerative colitis in mice through regulating macrophage polarization via SCFAs-SLC52A2/FFAR2 pathway

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

---

Antidepressant-like effects of hyperoside on chronic stress-induced depressive-like behaviors in mice: Gut microbiota and short-chain fatty acids

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 354, P. 356 - 367

Published: March 15, 2024

Language: Английский

---

Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Nutrients, Journal Year: 2024, Volume and Issue: 17(1), P. 143 - 143

Published: Dec. 31, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major contributor to liver-related morbidity, cardiovascular disease, and metabolic complications. Lifestyle interventions, including diet exercise, are first line in treating MASLD. Dietary approaches such as the low-glycemic-index Mediterranean diet, ketogenic intermittent fasting, high fiber diets have demonstrated potential addressing dysfunction underlying this condition. The development progression of MASLD closely associated with taxonomic shifts gut microbial communities, relationship well-documented literature. Given importance primary treatment for MASLD, it important understand how microbiota their byproducts mediate favorable outcomes induced by healthy dietary patterns. Conversely, changes conferred unhealthy patterns Western may induce dysbiosis influence through promoting hepatic inflammation, up-regulating lipogenesis, dysregulating bile acid metabolism, increasing insulin resistance, causing oxidative damage hepatocytes. Although emerging evidence has identified links between microbiota, significant gaps remain understanding specific roles, metabolite pathways, host interactions, causal relationships. Therefore, review aims provide mechanistic insights into role microbiota-mediated processes analysis both contribution pathophysiology. By better elucidating interplay nutrients, processes, onset work identify new opportunities targeted interventions treat efficiently.

Language: Английский

---

Biomimetic nanocarriers harnessing microbial metabolites usher the path for brain disease therapy

Nano TransMed, Journal Year: 2023, Volume and Issue: 2(4), P. 100020 - 100020

Published: Dec. 1, 2023

The gastrointestinal system, often regarded as the 'second brain of humanity,' maintains a profound connection with cerebral realm. Unlocking intricate metabolic pathways gut microorganisms is paramount in treatment ailments. This review primarily focuses on biomimetic precision nanocarriers, harnessing metabolites derived from microbiota, to target disorders. Elaborating constituents, it illuminates unique interplay between originating microbiota and domain. Moreover, underscores symbiotic relationship nanocarriers fashioned microbiota-derived augmentation well-being. Offering comprehensive outlook, this sheds light recent applications, challenges, future prospects rooted across spectrum disease treatments. It presents an expansive perspective attributes engineered metabolites, facilitating deeper understanding nexus these

Language: Английский

---

Changes in the fatty acid profiles and health indexes of bovine colostrum during the first days of lactation and their impact on human health

Food Chemistry, Journal Year: 2024, Volume and Issue: 448, P. 139042 - 139042

Published: March 19, 2024

Language: Английский

---

Probiotics and the Role of Dietary Substrates in Maintaining the Gut Health: Use of Live Microbes and Their Products for Anticancer Effects against Colorectal Cancer

Journal of Microbiology and Biotechnology, Journal Year: 2024, Volume and Issue: 34(10), P. 1933 - 1946

Published: Aug. 8, 2024

Language: Английский

---

Probiotic-Derived Bioactive Compounds in Colorectal Cancer Treatment

Microorganisms, Journal Year: 2023, Volume and Issue: 11(8), P. 1898 - 1898

Published: July 27, 2023

Colorectal cancer (CRC) is a multifactorial disease with increased morbidity and mortality rates globally. Despite advanced chemotherapeutic approaches for the treatment of CRC, low survival due to regular occurrence drug resistance deleterious side effects render need alternative anticancer agents imperative. Accumulating evidence supports that gut microbiota imbalance precedes establishment carcinogenesis, subsequently contributing progression response therapy. Manipulation composition via administration probiotic-derived bioactive compounds has gradually attained interest scientific communities as novel therapeutic strategy CRC. These encompass miscellaneous metabolic secreted products probiotics, including bacteriocins, short-chain fatty acids (SCFAs), lactate, exopolysaccharides (EPSs), biosurfactants, bacterial peptides, profound anti-inflammatory antiproliferative properties. This review provides classification postbiotic types comprehensive summary current state research on their biological role against It also describes how intricate interaction regulates proper function intestinal barrier, thus eliminating dysbiosis CRC development. Finally, it discusses future perspectives in precision-medicine well challenges synthesis optimization clinical studies.

Language: Английский

---

The Pro- vs. Anti-Angiogenic Capacity of Short Chain Fatty Acids is Dependent on the Bioavailability of FFAR3 in Peripheral Artery Disease.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Our current study builds on our recent report that showed Palmitate aggravates ischemic endothelial (EC) dysfunction in vitro and aims to determine whether is a critical determinant of PAD severity. In contrast Palmitate, we studied the role short-chain fatty acids (SCFAs) regulating revascularization PAD. Femoral artery ligation resection was used as preclinical-PAD model. Hypoxia serum starvation dramatically decreased ischemic-EC survival angiogenic capacity , whereas SCFAs significantly induced their capacity. LC-MRM MS analysis SCFA content ischemic-muscle. Laser Speckle perfusion imaging intramuscular treatment recovery, modest but significant impairment recovery. Immunoblot preferentially induce Free acid receptor (FFAR)-3, not FFAR2. Accordingly, silencing FFAR3 capacity, inhibiting FFAR2 angiogenesis. Pharmacological inhibition by beta-hydroxybutyrate (BHB) further recovery BHB-treated Mechanistically, FFAR3-induced FFAR2-levels inhibited decreasing NO inducing ROS levels SCFA-treated ischemic-ECs. data shows alone sufficient drive Increased ischemic-muscle allow activate AKT-NO axis angiogenesis However, loss promotes activation blocks SCFA-induced NO-production redox balance thereby preclinical-PAD.

Language: Английский

---